AI Article Synopsis
- The study investigates the potential causal relationship between Systemic Lupus Erythematosus (SLE) and osteoporosis, using Mendelian randomization (MR) methods.
- Researchers analyzed data from SLE genome-wide association studies (GWAS) and osteoporosis GWASs among individuals of East Asian descent, identifying 26 genetic variants linked to SLE that could influence osteoporosis risk.
- The results suggest a significant association, indicating SLE may increase the risk of developing osteoporosis, emphasizing the importance of monitoring osteoporosis in SLE patients.
Article Abstract
Background: Systemic Lupus Erythematosus (SLE) and Osteoporosis are two prevalent medical conditions. Previous studies have suggested a possible correlation between SLE and osteoporosis, though the underpinning causal relationship remains largely unknown. The current study aimed to elucidate the causal association between SLE and osteoporosis by employing a Mendelian randomization (MR) approach.
Methods: We performed two-sample MR analysis using the inverse variance-weighted (IVW), weighted median, and MR-Egger methods on publicly available summary statistics datasets using a SLE genome-wide association study (GWAS) as an exposure and osteoporosis GWASs in people with East Asia ancestry as outcomes. The pleiotropy and heterogeneity were examined using a variety of techniques, including the MR-Egger intercept, the MR-PRESSO approach, and the Cochran's Q test.
Results: We selected 26 single-nucleotide polymorphisms from a SLE GWAS as instrumental variables for osteoporosis. The IVW (p < 0.05) method results support a potential association between SLE and osteoporosis. MR-Egger intercept (p = 0.82) and MR-PRESSO global test (p = 0.80) did not suggest evidence of horizontal or directional pleiotropy. Cochran's Q test (p = 0.78) showed that there was no heterogeneity between IVs.
Conclusion: The results of MR analysis indicated that SLE is likely associated with an increased risk of osteoporosis incidence. Our findings highlight the need for increased awareness the potential risk of osteoporosis among SLE patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071324 | PMC |
| http://dx.doi.org/10.1186/s41927-024-00388-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.
Lupus Sci Med
January 2025
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Objective: Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.
Methods: A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included.
Late-onset Systemic Lupus Erythematosus.
Rheumatol Int
January 2025
Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Kraków, Kraków, Poland.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease (ARD) that results from the dysregulation of multiple innate and adaptive immune pathways. Late-onset SLE (Lo-SLE) is the term used when the disease is first diagnosed after 50-65 years, though the standard age cut-off remains undefined. Defining "late-onset" as lupus with onset after 50 years is more biologically plausible as this roughly corresponds to the age of menopause.
View Article and Find Full Text PDFLC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by inhibiting the TLR9/NF-κB signaling pathway.
Food Funct
January 2025
School of Life Sciences, Nanchang University, Nanchang 330031, China.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease often treated with glucocorticoids, which can lead to complications such as osteoporosis and an increased infection risk. Hence, identifying safe and effective treatment strategies is crucial. has shown promise in improving immune disorders.
View Article and Find Full Text PDFProgressive resisted exercise program combined with aerobic exercise on osteoporotic systemic lupus erythematous patients: a prospective randomized controlled trial.
Disabil Rehabil
December 2024
Department of Physical Therapy for Surgery, Faculty of Physical Therapy, Cairo University, Giza, Egypt.
Purpose: To investigate the effect of progressive resisted exercise (PRE) and aerobic exercise (AE) on bone mineral density (BMD), muscular strength, exercise capacity, and health related quality of life (HRQoL) in patients with osteoporotic systemic lupus erythematous (SLE).
Methods: This study was a single blinded randomized controlled trail. Eighty SLE participants, 30-50 years old, were randomly allocated into four equal groups.
Inhibitory effect of hydroxychloroquine on glucocorticoid-induced osteoporosis in lupus therapy.
Clin Transl Immunology
October 2024
Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China.
Article Synopsis
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease treated primarily with hydroxychloroquine (HCQ) and glucocorticoids (GCs), but the exact mechanisms of their combined effectiveness remain unclear.
- The study utilized specific models to assess how HCQ enhances the anti-inflammatory effects of GCs by lowering macrophage FcγRI expression and inhibits osteoclast formation, which helps mitigate bone loss.
- Findings suggest that HCQ not only boosts the anti-inflammatory response of GCs but also protects against bone deterioration in lupus patients, providing new insights into treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!